In the News

Jeffrey Miller, M.D.

TriKE and TetraKE Platforms to be Highlighted

LOS ANGELESFebruary 13, 2018 /PRNewswire/ --

Gamida Cell Logo

CAMBRIDGE, Mass., January 16, 2018 – Gamida Cell, a leading cellular and immune therapeutics company, today announced the initiation of a phase I study evaluating its proprietary NAM-expanded natural killer cells (NAM-NK Cells) in patients with relapsed or refractory CD20+ non-Hodgkin lymphoma (NHL) and multiple myeloma.

Dr. Geller

SAN DIEGO, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the first subject has been treated in the APOLLO study of FATE-NK100 in women with ovarian cancer resistant to, or recurrent on, platinum-based treatment.

Subject in Dose Cohort 2 Achieves Morphologic Leukemia-free State at Day 14

No Dose Limiting Toxicities Reported

SAN DIEGO, Nov. 10, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc.

Douglas Yee, MD, and colleagues from various cancer centers around the country, recently met with Senator Dianne Feinstein of California, and a number of other senators, to discuss NIH funding for cancer research. 

With important budget decisions taking place in Washington in the coming weeks, the group met with the members of Congress to stress the importance of the NIH and the funding that it provides for continued cancer research efforts.

Published by: 
Andrew Ranallo, Communications and Marketing Manager, University of Minnesota Medical School
October 31, 2017
normal vs cancer cells

There has been great interest in finding structural targets in cancer for the widely prescribed type 2 diabetes drug metformin. Metformin is a synthetic product derived from galegine, a guanide natural product found in French lilac. Documented use of galegine for human disease dates back to 1620, when John Parkinson first described the use of lilac plants for medicinal purposes in his treatise Theatrum Botanicum.

Douglas Yee, M.D.

Minnesota Researchers Receive $380,000 in Research Funding

DALLAS – September 26, 2017 – Susan G. Komen, the world’s leading breast cancer organization, today announced 2017 research funding of $30.7 million for 98 research grants, with a focus on new treatments and understanding of the most lethal forms and stages of breast cancer. Komen funding to institutions in 27 states and 7 countries also includes research into new screening technologies, treatments for metastatic and aggressive types of breast cancer and disparities in breast cancer outcomes.

The grants include $380,000 in new funding for research at one institution in Minnesota, bringing Komen’s total research investment in Minnesota to $17,059,120 since 1982.

Pages